Copyright © 2003 by the European Society of Cardiology.
Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty
a CardioThoracic Department, University of Pisa, Ospedale Cisanello, Pisa, Italy
b CNR, Clinical Physiology Institute, Pisa, Italy
c Oncology Department, University of Pisa, Ospedale Santa Chiara, Pisa, Italy
Received April 30, 2003; accepted May 8, 2003 * Correspondence: Anna S. Petronio, MD, CardioThoracic Department, University of Pisa, Ospedale Cisanello, Via Paradisa, 2, 56124 Pisa, Italy
Aim To investigate the effect of abciximab on microvascular integrity and left ventricular (LV) functional recovery in patients with acute myocardial infarction (MI) treated by primary coronary angioplasty (PTCA).
Methods and results Thirty-one patients (27 males; age 39–76 years) with first, acute MI (<6 h after onset) were randomized to receive either abciximab+primary PTCA (n=17) or primary PTCA alone (n=14). Baseline characteristics of the two groups were similar. Myocardial reperfusion was studied shortly after PTCA by corrected TIMI frame count (cTFC) and intracoronary myocardial contrast echocardiography (MCE), after 48 h by intravenous MCE using intermittent, harmonic power Doppler, and after 1 month by intravenous MCE and 99 mTc-tetrofosmin SPECT. The patients treated with abciximab showed a shorter cTFC (23±4 vs 30±9 frames; P<0.05), a more preserved microvascular integrity shortly after PTCA (77% vs 55%; P<0.01), after 48 h (86% vs 50%; P<0.005) and at 1-month follow-up (86% vs 54% by MCE, P<0.001, and 68% vs 60% by SPECT, P<0.005) than patients treated with PTCA alone. Abciximab patients also showed a better recovery of LV function, as demonstrated by greater reduction in wall motion score index (1.4±0.3 vs 1.5±0.2; P<0.05) and increase in LV ejection fraction (53±7% vs 48±5%; P<0.001).
Conclusions Abciximab improves microvascular perfusion and LV functional recovery in primary PTCA.
Key Words: Contrast echocardiography • primary PTCA • myocardial infarction • platelet inhibitors • coronary microcirculation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, et al. Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A Five-Year Prospective Study J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4271 - 4277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sharma, R. Makkar, and J. Lardizabal Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 136 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 E J Smith, A Mathur, and M T Rothman Recent advances in primary percutaneous intervention for acute myocardial infarction Heart, December 1, 2005; 91(12): 1533 - 1536. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dorffler-Melly, F. Mahler, D.-D. Do, J. Triller, and I. Baumgartner Adjunctive Abciximab Improves Patency and Functional Outcome in Endovascular Treatment of Femoropopliteal Occlusions: Initial Experience Radiology, December 1, 2005; 237(3): 1103 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, R. Grimaldi, and M. Chiariello Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction QJM, September 1, 2005; 98(9): 633 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leoncini, F. Bellandi, R. Sciagra, M. Maioli, A. Toso, A. Coppola, S. Sestini, A. Mennuti, R. P. Dabizzi, and A. Pupi Gated SPECT Evaluation of the Relationship Between Admission Troponin I, Myocardial Salvage, and Functional Recovery in Acute Myocardial Infarction Treated by Abciximab and Early Primary Angioplasty J. Nucl. Med., May 1, 2004; 45(5): 739 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.M.J. Marques and C.A. Visser Myocardial contrast echocardiography in the assessment of pharmacologic intervention of the reperfusion injury Eur. Heart J., January 1, 2003; 24(1): 19 - 20. [Full Text] [PDF]
|
|